Chemoprevention and treatment of experimental Cowden's disease by mTOR inhibition with rapamycin
- PMID: 18757421
- DOI: 10.1158/0008-5472.CAN-08-0922
Chemoprevention and treatment of experimental Cowden's disease by mTOR inhibition with rapamycin
Abstract
Cowden's disease is an autosomal dominant disorder characterized by the development of multiple mucocutaneous lesions and benign tumors, and enhanced cancer predisposition. Most Cowden's disease patients harbor inactivating mutations in the PTEN tumor suppressor gene which encodes a lipid phosphatase, PTEN, which restrains the phosphatidylinositol 3-kinase-Akt signaling pathway. We observed that the epithelial-specific deletion of Pten in mice causes multiple hyperproliferative and tumor lesions that strikingly resemble Cowden's disease. This animal model system provided an opportunity to explore novel therapeutic approaches in Cowden's disease. Indeed, we show here that rapamycin administration, which inhibits a key downstream _target of Akt, mammalian _target of rapamycin (mTOR), promotes the rapid regression of advanced mucocutaneous lesions. Furthermore, when administered before disease manifestation, rapamycin can halt the development of Cowden's disease-like lesions, thereby prolonging animal survival. These findings suggest that mTOR inhibition with rapamycin may represent a suitable therapeutic option for the chemoprevention and treatment of Cowden disease patients and others tumor syndromes that involve defective PTEN function.
Similar articles
-
Cowden's syndrome with immunodeficiency.J Med Genet. 2015 Dec;52(12):856-9. doi: 10.1136/jmedgenet-2015-103266. Epub 2015 Aug 5. J Med Genet. 2015. PMID: 26246517 Free PMC article.
-
Hamartoma-like lesions in the mouse retina: an animal model of Pten hamartoma tumour syndrome.Dis Model Mech. 2018 May 21;11(5):dmm031005. doi: 10.1242/dmm.031005. Dis Model Mech. 2018. PMID: 29716894 Free PMC article.
-
Primary lung adenocarcinoma occurring in a PTEN related syndrome (Cowden's disease): routine EGFR sequencing also highlights two rare somatic mutations S768I and V769L.Lung Cancer. 2013 Mar;79(3):318-20. doi: 10.1016/j.lungcan.2012.11.020. Epub 2012 Dec 20. Lung Cancer. 2013. PMID: 23261230
-
Mucocutaneous papillomatous papules in Cowden's syndrome.Clin Exp Dermatol. 2008 Mar;33(2):151-3. doi: 10.1111/j.1365-2230.2007.02602.x. Epub 2007 Nov 15. Clin Exp Dermatol. 2008. PMID: 18021272 Review.
-
Dysregulation of the mTOR pathway secondary to mutations or a hostile microenvironment contributes to cancer and poor wound healing.J Invest Dermatol. 2009 Mar;129(3):529-31. doi: 10.1038/jid.2008.441. J Invest Dermatol. 2009. PMID: 19209152 Review.
Cited by
-
Exploiting PI3K/mTOR signaling to accelerate epithelial wound healing.Oral Dis. 2013 Sep;19(6):551-8. doi: 10.1111/odi.12070. Epub 2013 Feb 4. Oral Dis. 2013. PMID: 23379329 Free PMC article. Review.
-
The metabolic basis of kidney cancer.Semin Cancer Biol. 2013 Feb;23(1):46-55. doi: 10.1016/j.semcancer.2012.06.002. Epub 2012 Jun 13. Semin Cancer Biol. 2013. PMID: 22705279 Free PMC article. Review.
-
Advances in Molecular Mechanisms of Kidney Disease: Integrating Renal Tumorigenesis of Hereditary Cancer Syndrome.Int J Mol Sci. 2024 Aug 21;25(16):9060. doi: 10.3390/ijms25169060. Int J Mol Sci. 2024. PMID: 39201746 Free PMC article. Review.
-
The gene dosage of class Ia PI3K dictates the development of PTEN hamartoma tumor syndrome.Cell Cycle. 2013 Dec 1;12(23):3589-93. doi: 10.4161/cc.26812. Epub 2013 Oct 15. Cell Cycle. 2013. PMID: 24131925 Free PMC article.
-
Immunohistochemical and molecular profiles of heterogeneous components of metaplastic breast cancer: a squamous cell carcinomatous component was distinct from a spindle cell carcinomatous component.Discov Oncol. 2024 Apr 2;15(1):95. doi: 10.1007/s12672-024-00950-0. Discov Oncol. 2024. PMID: 38564036 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous
